New Delhi : Biocon’s contract research arm Syngene International has established an integrated, multi-disciplinary drug discovery and development centre for Amgen in Bengaluru.
The centre, named Syngene Amgen Research and Development Center (SARC), will be Syngene’s fourth such exclusive R&D unit, the company said in a filing to BSE.
It, however, did not disclose the cost of establishing the centre.
The company already operates dedicated R&D centres for Bristol-Myers Squibb, Abbott Nutrition and Baxter, Syngene International said.
“Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene’s scientific teams to deliver world-class science towards our partners’ R&D programmes in both biotechnology and small molecule medicines,” Syngene International CEO Jonathan Hunt said.
With the establishment of SARC, the association of the company and Amgen now extends into a collaboration spanning capabilities in medicinal and process chemistry, bio logics, bio process, drug metabolism, pharma cokinetics, bio analytical research, and pharmaceutical development, Syngene said.
Latest posts by savita thakur (see all)
- 2000 medicines to become up to 90 percent cheaper: Nadda - November 7, 2016
- Drugmakers under fire for possible US price fixing - November 7, 2016
- Pharma cos see huge sell off: Sun Pharma, Dr Reddys hit hard - November 7, 2016